Plasma Levels of Growth Differentiation Factor-15 and Adverse Kidney Outcomes
Clinical Journal of the American Society of Nephrology · 2026-11 · 21 (11) · 1899-1913
DOI: 10.2215/cjn.0000001177 ↗Abstract
Key Points Elevated growth differentiation factor-15 was associated with higher CKD risk, whereas Mendelian randomization suggested a possible protective association with kidney function. Proteomics identified TNF receptor signaling, extracellular matrix organization, and leukocyte chemotaxis as candidate pathways. Growth differentiation factor-15 may serve as a prognostic biomarker, while its possible protective role and underlying mechanisms require further study. Background Growth differentiation factor-15 (GDF-15) has been implicated in adverse outcomes in cardiovascular disease and diabetes, highlighting its potential as a prognostic marker. However, its association with CKD development remains unclear. Therefore, we investigated the association between GDF-15 and incident CKD and explored potential causal mechanisms. Methods We analyzed 31,965 UK Biobank participants without preexisting CKD. The primary outcome was incident CKD, defined by diagnostic codes or an eGFR
EUVIMED